Press Releases Check out the latest news from Tavanta May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer August 31, 2020 Tavanta Therapeutics, a New Specialty Pharmaceutical Company, Has Diverse Pipeline of Novel Drugs and Risk-balanced Approach to Product Development October 29, 2019 DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT-45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer October 21, 2019 Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and New President of DRGT Research September 18, 2019 DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99) July 15, 2019 DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure June 10, 2019 DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor February 05, 2019 DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development 12>>
